Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$208,018 | -$338,790 | -$83,815 | -$65,801 |
| Dep. & Amort. | $0 | $744 | $1,567 | $1,576 |
| Deferred Tax | $0 | $0 | -$327 | $0 |
| Stock-Based Comp. | $44,833 | $25,675 | $7,111 | $8,038 |
| Change in WC | -$4,534 | -$5,206 | -$5,503 | $1,833 |
| Other Non-Cash | $10,309 | $217,667 | $823 | $638 |
| Operating Cash Flow | -$157,410 | -$99,910 | -$80,144 | -$53,716 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | -$38 | -$573 |
| Net Acquisitions | $0 | $3,035 | $0 | $0 |
| Inv. Purchases | -$599,252 | -$166,803 | -$39,500 | -$133,079 |
| Inv. Sales/Matur. | $245,967 | $39,900 | $96,546 | $111,033 |
| Other Inv. Act. | $0 | $15,475 | $0 | $0 |
| Investing Cash Flow | -$353,285 | -$108,393 | $57,008 | -$22,619 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$16 | -$418 | -$510 |
| Stock Issued | $236,382 | $169,110 | $42,874 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $174,524 | $191,983 | $222 | $1,903 |
| Financing Cash Flow | $410,906 | $361,077 | $42,678 | $1,393 |
| Forex Effect | -$3 | $25 | -$106 | -$15 |
| Net Chg. in Cash | -$99,792 | $152,799 | $19,436 | -$74,957 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $189,215 | $36,416 | $16,980 | $91,937 |
| End Cash | $89,423 | $189,215 | $36,416 | $16,980 |
| Free Cash Flow | -$157,410 | -$99,910 | -$80,182 | -$54,289 |